Redefining the gut as the motor of critical illness

Trends in Molecular Medicine

Volumn 20, Issue 4, 2014, Pages 214-223

  Mittal, Rohit ^a   Coopersmith, Craig M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Critical illness intestine; Epithelium; Gut; Microbiome; Sepsis

Indexed keywords

APOPTOSIS; CRITICAL ILLNESS; HUMAN; INFLAMMATION; INTESTINE; INTESTINE EPITHELIUM; INTESTINE MUCOSA; LYMPH; MICROBIOME; MICROORGANISM; MOTOR PERFORMANCE; MULTIPLE ORGAN FAILURE; NONHUMAN; REVIEW; VIRULENCE;

CRITICAL ILLNESS INTESTINE; EPITHELIUM; GUT; MICROBIOME; SEPSIS;

ANIMALS; CRITICAL ILLNESS; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL MUCOSA; LYMPHATIC VESSELS; MICROBIOTA; SEPSIS;

EID: 84897463412     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.08.004     Document Type: Review

References (98)

1. Carrico C.J., et al. Multiple-organ-failure syndrome. The gastrointestinal tract: the "motor" of MOF. Arch. Surg. 1986, 121:196-208.
2. Clark J.A., Coopersmith C.M. Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness. Shock 2007, 28:384-393.
3. Coopersmith C.M., et al. A comparison of critical care research funding and the financial burden of critical illness in the United States. Crit. Care Med. 2012, 40:1072-1079.
4. Gaieski D.F., et al. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med. 2013, 41:1167-1174.
5. Deitch E.A. Gut-origin sepsis: evolution of a concept. Surgeon 2012, 10:350-356.
6. Deitch E.A. Gut lymph and lymphatics: a source of factors leading to organ injury and dysfunction. Ann. N. Y. Acad. Sci. 2010, 21207(Suppl. 1):E103-E111.
7. Fink M.P., et al. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit. Care Clin. 2005, 21:177-196.
8. Swank G.M., et al. Role of the gut in multiple organ failure: bacterial translocation and permeability changes. World J. Surg. 1996, 20:411-417.
9. Yoseph B.P., et al. Chronic alcohol ingestion increases mortality and organ injury in a murine model of septic peritonitis. PLoS ONE 2013, 8:e62792.
10. Purohit V., et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol 2008, 42:349-361.
11. Moore F.A., et al. Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. J. Trauma 1991, 31:629-636.
12. Watkins A.C., et al. Mesenteric lymph duct ligation attenuates lung injury and neutrophil activation after intraperitoneal injection of endotoxin in rats. J. Trauma 2008, 64:126-130.
13. Senthil M., et al. Intravenous injection of trauma-hemorrhagic shock mesenteric lymph causes lung injury that is dependent upon activation of the inducible nitric oxide synthase pathway. Ann. Surg. 2007, 246:822-830.
14. Lee M.A. Role of gut-lymph factors in the induction of burn-induced and trauma-shock-induced acute heart failure. Int. J. Clin. Exp. Med. 2008, 1:171-180.
15. Sambol J.T., et al. Mesenteric lymph duct ligation prevents trauma/hemorrhage shock-induced cardiac contractile dysfunction. J. Appl. Physiol. 2009, 106:57-65.
16. Kawai K., et al. Cellular mechanisms of burn-related changes in contractility and its prevention by mesenteric lymph ligation. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H2475-H2484.
17. Badami C.D., et al. Mesenteric lymph duct ligation improves survival in a lethal shock model. Shock 2008, 30:680-685.
18. Sarin E.L., et al. Systemic neutrophil priming by lipid mediators in post-shock mesenteric lymph exists across species. J. Trauma 2004, 57:950-954.
19. Fang J.F., et al. Proteomic analysis of post-hemorrhagic shock mesenteric lymph. Shock 2010, 34:291-298.
20. Mittal A., et al. Changes in the mesenteric lymph proteome induced by hemorrhagic shock. Shock 2010, 34:140-149.
21. Peltz E.D., et al. Proteome and system ontology of hemorrhagic shock: exploring early constitutive changes in postshock mesenteric lymph. Surgery 2009, 146:347-357.
22. Caputo F.J., et al. Pancreatic duct ligation abrogates the trauma hemorrhage-induced gut barrier failure and the subsequent production of biologically active intestinal lymph. Shock 2007, 28:441-446.
23. Deitch E.A., et al. Anticoagulants influence the in vitro activity and composition of shock lymph but not its in vivo activity. Shock 2011, 36:177-183.
24. Qin Y., et al. Heparin use in a rat hemorrhagic shock model induces biologic activity in mesenteric lymph separate from shock. Shock 2011, 35:411-421.
25. Qin X., et al. Role of lipase-generated free fatty acids in converting mesenteric lymph from a noncytotoxic to a cytotoxic fluid. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303:G969-G978.
26. Reino D.C., et al. Trauma hemorrhagic shock-induced lung injury involves a gut-lymph-induced TLR4 pathway in mice. PLoS ONE 2011, 6:e14829.
27. Reino D.C., et al. Activation of Toll-like receptor 4 is necessary for trauma hemorrhagic shock-induced gut injury and polymorphonuclear neutrophil priming. Shock 2012, 38:107-114.
28. Xie Y., et al. Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency. J. Biol. Chem. 2006, 281:4075-4086.
29. Dominguez J.A., et al. Intestine-specific Mttp deletion decreases mortality and prevents sepsis-induced intestinal injury in a murine model of Pseudomonas aeruginosa pneumonia. PLoS ONE 2012, 7:e49159.
30. Kruger P., et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am. J. Respir. Crit. Care Med. 2013, 187:743-750.
31. Zahs A., et al. Inhibition of long myosin light-chain kinase activation alleviates intestinal damage after binge ethanol exposure and burn injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303:G705-G712.
32. Mizuno T., et al. Intraoperative bacterial translocation detected by bacterium-specific ribosomal RNA-targeted reverse-transcriptase polymerase chain reaction for the mesenteric lymph node strongly predicts postoperative infectious complications after major hepatectomy for biliary malignancies. Ann. Surg. 2010, 252:1013-1019.
33. Bellot P., et al. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int. 2013, 33:31-39.
34. Neal M.D., et al. Toll-like receptor 4 is expressed on intestinal stem cells and regulates their proliferation and apoptosis via the p53 up-regulated modulator of apoptosis. J. Biol. Chem. 2012, 287:37296-37308.
35. Neal M.D., et al. Intestinal stem cells and their roles during mucosal injury and repair. J. Surg. Res. 2011, 167:1-8.
36. Benton S.M., et al. Differential regulation of tissue thiol-disulfide redox status in a murine model of peritonitis. J. Inflamm. (Lond.) 2012, 9:36.
37. Coopersmith C.M., et al. Sepsis from Pseudomonas aeruginosa pneumonia decreases intestinal proliferation and induces gut epithelial cell cycle arrest. Crit. Care Med. 2003, 31:1630-1637.
38. Perrone E.E., et al. Mechanisms of methicillin-resistant Staphylococcus aureus pneumonia-induced intestinal epithelial apoptosis. Shock 2012, 38:68-75.
39. Neal M.D., et al. A critical role for TLR4 induction of autophagy in the regulation of enterocyte migration and the pathogenesis of necrotizing enterocolitis. J. Immunol. 2013, 190:3541-3551.
40. Dominguez J.A., et al. Epidermal growth factor improves survival and prevents intestinal injury in a murine model of Pseudomonas aeruginosa pneumonia. Shock 2011, 36:381-389.
41. Rupani B., et al. Relationship between disruption of the unstirred mucus layer and intestinal restitution in loss of gut barrier function after trauma hemorrhagic shock. Surgery 2007, 141:481-489.
42. Fink M.P. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr. Opin. Crit. Care 2003, 9:143-151.
43. Hotchkiss R.S., et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 1999, 27:1230-1251.
44. Takasu O., et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am. J. Respir. Crit. Care Med. 2013, 187:509-517.
45. Fox A.C., et al. Cancer causes increased mortality and is associated with altered apoptosis in murine sepsis. Crit. Care Med. 2010, 38:886-893.
46. Turnbull I.R., et al. Age disproportionately increases sepsis-induced apoptosis in the spleen and gut epithelium. Shock 2004, 22:364-368.
47. Vyas D., et al. Epithelial apoptosis in mechanistically distinct methods of injury in the murine small intestine. Histol. Histopathol. 2007, 22:623-630.
48. Coopersmith C.M., et al. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA 2002, 287:1716-1721.
49. Coopersmith C.M., et al. Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Crit. Care Med. 2002, 30:195-201.
50. Husain K.D., et al. BCL-2 inhibits gut epithelial apoptosis induced by acute lung injury in mice but has no effect on survival. Shock 2003, 20:437-443.
51. Andersen J.L., et al. The tangled circuitry of metabolism and apoptosis. Mol. Cell 2013, 49:399-410.
52. + lymphocytes control gut epithelial apoptosis and mediate survival in sepsis. FASEB J. 2009, 23:1817-1825.
53. McConnell K.W., et al. The role of heat shock protein 70 in mediating age-dependent mortality in sepsis. J. Immunol. 2011, 186:3718-3725.
54. Dominguez J.A., et al. Can we protect the gut in critical illness? The role of growth factors and other novel approaches. Crit. Care Clin. 2010, 26:549-565.
55. Clark J.A., et al. Epidermal growth factor treatment decreases mortality and is associated with improved gut integrity in sepsis. Shock 2008, 30:36-42.
56. Clark J.A., et al. Enterocyte-specific epidermal growth factor prevents barrier dysfunction and improves mortality in murine peritonitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297:G471-G479.
57. Inoue S., et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J. Immunol. 2010, 184:1401-1409.
58. Chang M., et al. Breakdown of mucin as barrier to digestive enzymes in the ischemic rat small intestine. PLoS ONE 2012, 7:e40087.
59. Chang M., et al. Disruption of the mucosal barrier during gut ischemia allows entry of digestive enzymes into the intestinal wall. Shock 2012, 37:297-305.
60. DeLano F.A., et al. Pancreatic digestive enzyme blockade in the intestine increases survival after experimental shock. Sci. Transl. Med. 2013, 5:169ra11.
61. Schmid-Schonbein G.W., et al. An elementary analysis of physiologic shock and multi-organ failure: the autodigestion hypothesis. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2012, 2012:3114-3115.
62. Qin X., et al. Hydrophobicity of mucosal surface and its relationship to gut barrier function. Shock 2008, 29:372-376.
63. Lu Q., et al. The anatomic sites of disruption of the mucus layer directly correlate with areas of trauma/hemorrhagic shock-induced gut injury. J. Trauma 2011, 70:630-635.
64. Sheth S.U., et al. Intestinal mucus layer preservation in female rats attenuates gut injury after trauma-hemorrhagic shock. J. Trauma 2010, 68:279-288.
65. Fishman J.E., et al. Oxidative modification of the intestinal mucus layer is a critical but unrecognized component of trauma hemorrhagic shock-induced gut barrier failure. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304:G57-G63.
66. Sharpe S.M., et al. Loss of the intestinal mucus layer in the normal rat causes gut injury but not toxic mesenteric lymph nor lung injury. Shock 2010, 34:475-481.
67. Qin X., et al. The mucus layer is critical in protecting against ischemia-reperfusion-mediated gut injury and in the restitution of gut barrier function. Shock 2011, 35:275-281.
68. McConnell K.W., et al. Epithelial cells. Crit. Care Med. 2005, 33:S520-S522.
69. Chen C., et al. Myosin light chain kinase mediates intestinal barrier disruption following burn injury. PLoS ONE 2012, 7:e34946.
70. Turner J.R. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 2009, 9:799-809.
71. Shen L. Tight junctions on the move: molecular mechanisms for epithelial barrier regulation. Ann. N. Y. Acad. Sci. 2012, 1258:9-18.
72. Geng Y., et al. Epidermal growth factor promotes proliferation and improves restoration after intestinal ischemia-reperfusion injury in rats. Inflammation 2013, 36:670-679.
73. Yang J., et al. Heparin-binding epidermal growth factor-like growth factor improves intestinal barrier function and reduces mortality in a murine model of peritonitis. Surgery 2013, 153:52-62.
74. Su Y., et al. HB-EGF promotes intestinal restitution by affecting integrin-extracellular matrix interactions and intercellular adhesions. Growth Factors 2013, 31:39-55.
75. Chen C.L., et al. Heparin-binding EGF-like growth factor protects intestinal stem cells from injury in a rat model of necrotizing enterocolitis. Lab. Invest. 2012, 92:331-344.
76. Shah K.G., et al. Recombinant human milk fat globule-EGF factor 8 produces dose-dependent benefits in sepsis. Intensive Care Med. 2012, 38:128-136.
77. Zhang F., et al. Milk fat globule epidermal growth factor-factor 8 mitigates inflammation and tissue injury after hemorrhagic shock in experimental animals. J. Trauma Acute Care Surg. 2012, 72:861-869.
78. Schuijt T.J., et al. The intestinal microbiota and host immune interactions in the critically ill. Trends Microbiol. 2013, 21:221-229.
79. Arumugam M., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
80. Cho I., et al. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 2012, 13:260-270.
81. Fox A.C., et al. The endogenous bacteria alter gut epithelial apoptosis and decrease mortality following Pseudomonas aeruginosa pneumonia. Shock 2012, 38:508-514.
82. Fagundes C.T., et al. Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice. J. Immunol. 2012, 188:1411-1420.
83. Ferraro F.J., et al. A comparison of survival at different degrees of hemorrhagic shock in germ-free and germ-bearing rats. Shock 1995, 4:117-120.
84. Souza D.G., et al. The essential role of the intestinal microbiota in facilitating acute inflammatory responses. J. Immunol. 2004, 173:4137-4146.
85. Seal J.B., et al. Agent-based dynamic knowledge representation of Pseudomonas aeruginosa virulence activation in the stressed gut: towards characterizing host-pathogen interactions in gut-derived sepsis. Theor. Biol. Med. Model. 2011, 8:33.
86. Patel N.J., et al. Recognition of intestinal epithelial HIF-1α activation by Pseudomonas aeruginosa. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G134-G142.
87. Wu L., et al. Recognition of host immune activation by Pseudomonas aeruginosa. Science 2005, 309:774-777.
88. Fink D., et al. Pseudomonas aeruginosa potentiates the lethal effect of intestinal ischemia-reperfusion injury: the role of in vivo virulence activation. J. Trauma 2011, 71:1575-1582.
89. Babrowski T., et al. The intestinal environment of surgical injury transforms Pseudomonas aeruginosa into a discrete hypervirulent morphotype capable of causing lethal peritonitis. Surgery 2013, 153:36-43.
90. Romanowski K., et al. Candida albicans isolates from the gut of critically ill patients respond to phosphate limitation by expressing filaments and a lethal phenotype. PLoS ONE 2012, 7:e30119.
91. Zaborin A., et al. Red death in Caenorhabditis elegans caused by Pseudomonas aeruginosa PAO1. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6327-6332.
92. Lamarche M.G., et al. The phosphate regulon and bacterial virulence: a regulatory network connecting phosphate homeostasis and pathogenesis. FEMS Microbiol. Rev. 2008, 32:461-473.
93. Zaborin A., et al. Pseudomonas aeruginosa overrides the virulence inducing effect of opioids when it senses an abundance of phosphate. PLoS ONE 2012, 7:e34883.
94. Romanowski K., et al. Prevention of siderophore-mediated gut-derived sepsis due to P. aeruginosa can be achieved without iron provision by maintaining local phosphate abundance: role of pH. BMC Microbiol. 2011, 11:212.
95. Shimizu K., et al. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig. Dis. Sci. 2011, 56:1171-1177.
96. Shimizu K., et al. Probiotic/synbiotic therapy for treating critically ill patients from a gut microbiota perspective. Dig. Dis. Sci. 2013, 58:23-32.
97. Khailova L., et al. Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis. Anesthesiology 2013, 119:166-177.
98. van Nood N.E., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 2013, 368:407-415.